---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-25-017208"
form_type: "8-K"
ticker: "KAPA"
cik: "0001962011"
company_name: "Kairos Pharma, LTD."
filed_at: "2025-10-07T23:59:59+00:00"
generated_at: "2026-05-17T04:30:17.826195+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Kairos Pharma to Present Phase 2 Prostate Cancer Data at ESMO 2025

## Summary
- On October 7, 2025, Kairos issued press release announcing ESMO Congress presentation in Berlin from October 17-21.
- Presentation covers interim analysis of Phase 2 trial evaluating ENV105 (carotuximab) plus apalutamide in mCRPC.
- Trial enrolling 100 men at Cedars-Sinai, City of Hope, and Huntsman Cancer Institute.
- On October 1, 2025, Kairos Board approved novation agreements with Cedars-Sinai and Tracon to transfer patent licenses from Enviro to Kairos.
- Transferred patents include exclusive licenses for mitochondrial DNA depletion and endoglin antagonism therapies.

## SEC filing metadata
- accession: 0001493152-25-017208
- form_type: 8-K
- ticker: KAPA
- cik: 0001962011
- company_name: Kairos Pharma, LTD.
- filed_at: 2025-10-07T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1962011/000149315225017208/0001493152-25-017208-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1962011/000149315225017208/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-25-017208
- JSON: https://secwatch.observer/filing/0001493152-25-017208.json
- Plain text: https://secwatch.observer/filing/0001493152-25-017208.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.